Dr. O'Reilly on Immunotherapy in Pancreatic Cancer

Video

Eileen O'Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy in patients with pancreatic cancer.

Eileen O'Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy in patients with pancreatic cancer.

According to O'Reilly, there is compelling science and biology behind using immunotherapy combinations in pancreatic cancer, since single-agent checkpoint inhibitors are insufficient.

In pancreatic cancer, the most promising combination is immunotherapy with a cytotoxic backbone, says O'Reilly. The disease needs to be under control for immunotherapy to work, which is why this combination has become a focus for this patient population.

Related Videos
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD